Loss of spatacsin function alters lysosomal lipid clearance leading to upper and lower motor neuron degeneration.
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3 Introduction:
Hereditary spastic paraplegias (HSP) constitute the second most common group of motor neuron diseases. They are characterized by progressive bilateral weakness, spasticity and the loss of vibration sensation in the lower limbs. These symptoms are mostly due to the degeneration of upper motor neuron axons in the corticospinal tracts (Harding, 1983) . The main causes of autosomal recessive HSP are mutations in the SPG11 gene. Symptoms of SPG11 patients generally appear during the first decade of life and, in addition to spastic gait disorder, include cognitive impairment, mental retardation, peripheral neuropathy, cerebellar ataxia, parkinsonism and retinal degeneration (Anheim et al., 2009; Puech et al., 2011; Stevanin et al., 2008) . These symptoms are often associated with progressive thinning of the corpus callosum and white matter hyperintensities by brain magnetic resonance imaging (MRI) (Hehr et al., 2007; Stevanin et al., 2007) . Mutations in SPG11 also account for autosomal-recessive Charcot Marie Tooth (CMT) disease (Montecchiani et al., 2016) and slowly progressive juvenile-onset autosomal recessive amyotrophic lateral sclerosis (ALS) without cognitive impairment or abnormal MRI (Daoud et al., 2012; Orlacchio et al., 2010) . In agreement, a recent neuropathological analysis of the brain from two patients with the full-blown SPG11 phenotype showed that the pathology partially mimics ALS lesions (Denora et al., 2016) .
SPG11 encodes a 2,443-amino acid protein called spatacsin. Regardless of the associated phenotype, the vast majority of mutations identified in SPG11 patients are nonsense or frameshift mutations, which are predicted to lead to the loss of function of spatacsin (Montecchiani et al., 2016; Orlacchio et al., 2010; Stevanin et al., 2008) . The nature of the mutation is not responsible for the variability in phenotype as intrafamilial phenotypic variability has been observed, with the same mutations leading to juvenile ALS in one patient and HSP with a thin corpus callosum in his sibling (Daoud et al., 2012) .
Spatacsin interacts with proteins involved in membrane-trafficking (Hirst et al, 2015) , among which AP5Z1 (SPG48) and spastizin/zFYVE26 (SPG15) are also implicated in hereditary spastic paraplegia, when mutated (Hanein et al, 2008; Slabicki et al, 2010) . The symptoms of patients mutated in the SPG15 or SPG11 gene are very similar (Hanein et al., 2008) , in agreement with their involvement in the same cellular mechanisms. Indeed, recent investigations in fibroblasts of SPG11 and SPG15 patients (Renvoise et al., 2014) and studies in mouse models have suggested that the loss of spatacsin or spastizin alters the function of the endolysosomal system (Khundadze et al., 2013;  A C C E P T E D M A N U S C R I P T 4 Varga et al., 2015) . Furthermore, spatacsin and spastizin have been shown to be involved in lysosome-recycling after fusion with autophagosomes in HeLa cells (Chang et al., 2014) . In agreement, an Spg11 knockout mouse model, obtained by inserting a genetrap cassette in the first intron of the Spg11 gene, showed that the loss of spatacsin impairs autolysosome reformation, ultimately leading to depletion of lysosomes and impaired autophagic clearance (Varga et al., 2015) .
This Spg11 model reproduced the neurodegeneration in the motor cortex and cerebellum observed in SPG11 patients, but did not show any early-onset motor or cognitive deficits, amyotrophy or alterations of the corpus callosum as frequently observed in SPG11 patients.
We therefore extensively characterized a new Spg11 knockout mouse model. These Spg11 -/animals displayed early-onset motor and cognitive deficits as well as signs of peripheral neuropathy, recapitulating the human disease. These deficits were paralleled by neurodegeneration in the motor cortex, cerebellum, hippocampus, and spinal cord as well as alterations of neuromuscular junctions and muscular atrophy. This degeneration was accompanied by an accumulation of lipid material in lysosomal structures, similar to the observations made in human SPG11 brains (Denora et al., 2016) .
Investigation of primary cultures of mouse embryonic fibroblasts and cortical neurons showed that this accumulation was due to the loss of lipid clearance in lysosomes normally promoted by spatacsin.

Results:
We investigated the physiological role of spatacsin by disrupting the expression of Spg11 in mice by inserting two successive stop codons in exon 32 of the gene ( Fig. 1 A) , the most frequently mutated exon in SPG11 patients (Stevanin et al., 2008; Stevanin et al., 2007) . When heterozygous mice (Spg11 +/-) were mated, knockout mice were generated in the expected Mendelian ratio and were viable. They developed normally, were fertile and had survival rates similar to those of their wild-type and heterozygous littermates (data not shown). We used western blotting to verify that the disruption of the Spg11 gene resulted in spatacsin depletion ( Fig. 1 B) . Spatacsin has been shown to interact with spastizin/zFYVE26. Thus, we tested whether the loss of spatacsin affected spastizin expression levels. As observed in patient fibroblasts (Renvoise et al., 2014) , spastizin levels in Spg11 -/brain samples were 9.0% ± 3.8% (n = 3) of those of control (Spg11 +/+ ) brain samples ( Fig. 1 B) .
Spg11
-/mice had no dysmorphic features or abnormalities up to the age of eight months relative to control littermates (data not shown). However, at 16 months, the age at which we stopped the study for ethical reasons, most of the knockout mice had an abnormal posture with spread hind limbs, lower pelvic elevation and pronounced kyphosis of the thoracic spine ( Fig. 1 C and D) .
Spg11-knockout mice develop an early-onset motor deficit
We evaluated the consequences of the loss of function of spatacsin on motor functions by performing a series of complementary behavioral tests. From the age of four months onwards, Spg11 -/mice displayed a progressive gait disorder and ataxia, which were quantified by recording the walking of mice on a treadmill at moderate speed (10 cm.s -1 ) ( Fig. 2 A ,B and C) . This test showed that gait angle, the position of the hind paws relative to the axis of the body, was significantly higher in knockout mice than in control mice, from the age of four months onwards ( Fig. 2 A and B ). With age,
Spg11
-/mice displayed a spreading of the hind limbs and began to drag their feet slightly during a forced walk (data not shown). We evaluated a possible ataxic gait by analyzing step sequence regularity, which reflects motor coordination. The regularity of the step sequence of Spg11 -/mice was much lower than that of Spg11 +/+ mice from eight months of age ( Fig. 2 C) . The motor deficit was even more marked in the rotarod test, a forced-run-paradigm. Spg11 -/mice displayed the first signs of motor impairment at the age of only six weeks in this test. The knockout mice remained on an accelerating rotarod for significantly less time than heterozygous and control mice, and could not
reach the same maximum speed on the rotarod apparatus (Fig. 2 D and E) . This motor deficit worsened with time. Motor performance decreased with age in control and heterozygous mice, but was systematically better in these mice than in the knockout mice.
Loss of spatacsin causes a cognitive deficit in mice.
We subjected mice to the Y-maze spontaneous-alternation test to evaluate any cognitive deficits. This test relies on the tendency of mice to explore new environments and is used to monitor spatial memory (Hughes, 2004) (Fig. 2 F) . During the first phase, mice were allowed to freely explore the only open arm of the maze and were confined there for one minute by closing a door behind them.
During the second phase, they were placed at the entrance of the maze with both arms open. As expected, Spg11 +/+ and Spg11 +/mice naturally chose to explore the unknown arm of the maze, a new environment, in ~75% of the trials, rather than the part of the maze that had already been explored. In contrast, Spg11 -/mice showed a lower tendency to enter the unknown arm than the Spg11 +/+ mice at six weeks of age, and from four months on, the Spg11 -/mice showed no preference between the visited and unknown arms ( Fig. 2 G) , suggesting an alteration in short-term spatial working memory in the knockout mice. We performed a fear conditioning experiment, in which a neutral context was associated with two aversive electric shocks, to determine whether different types of memory were affected. Freezing normally reflects the stress behavior in response to an aversive stimulus. The freezing baseline slightly increased with age, but we observed no significant differences between knockout mice and wild-type or heterozygous littermates. The two electric shocks triggered a marked increase of freezing in all groups (Fig. 2 H) . The next day, the percentage of time that wild-type and heterozygous mice spent in a frozen posture without an electric shock was high, showing that the task was learned. In contrast, Spg11 -/mice spent less time in a frozen posture from eight months on ( Fig.   2I ), suggesting that the knockout mice had a long-term emotional memory deficit.
Loss of spatacsin causes cortical, cerebellar and hippocampal atrophy.
We investigated whether the observed behavioral phenotypes resulted from neurodegeneration by analyzing the cortex, cerebellum and hippocampus of Spg11 -/mice. We measured the surface-areas of the brain and cortex on coronal brain sections (Bregma 0.90 to 0.60 mm) ( Fig. 3 A-E). The surface-area of the brain was lower in the Spg11 -/than wild type mice only at 16 months ( Fig. 3 D) , but the surface-area of the cortex was lower from eight months onwards ( Fig. 3 A C C E P T E D M A N U S C R I P T 7 E). The surface-area of the corpus callosum was affected after only four months ( Fig. 3F ). We then determined the number of cortical neurons in the primary motor cortex by immunostaining coronal sections of the brain for NeuN ( Fig. 3 G, H, and I). The number of neurons in the cortical layers was unaffected in four-month-old Spg11 -/mice, but from the age of eight months on, it was significantly lower than in Spg11 +/+ mice ( Fig. 3 J and K). Neuronal degeneration worsened with time and was accompanied by astrogliosis, as shown by an increase in GFAP-positive cells ( Fig. 3 H, I, M, and N).
We also observed increased levels of active caspase-3 in the cortex of Spg11 -/mice, suggesting that neuronal death occurs via an apoptotic pathway ( Fig. 3 L) .
Similarly, we measured the surface-areas of coronal sections of the cerebellum (Bregma -6.00
to -6.30 mm) ( Fig. 4 A) and showed that this structure was atrophied in Spg11 -/mice from eight months on ( Fig. 4 B) . Accordingly, the degeneration of Purkinje cells, labeled by Calbindinimmunostaining, followed a similar time course and was also accompanied by marked astrogliosis ( Fig. 4 C, D, and E).
As the Spg11 -/mice displayed memory deficits, we examined the hippocampus by labeling neurons with anti-NeuN antibodies and astrocytes with anti-GFAP antibodies (Fig. 4 , G and H). We measured the surface-area of the hippocampus in brain coronal sections (Bregma -1.70 to -2.00 mm) ( Fig. 4 F) . Spg11 -/mice exhibited atrophy of the hippocampus relative to the control mice from four months on ( Fig. 4 G-I). The surface-areas of the granule layer of the CA1 region and the dentate gyrus were lower in the knockout than control mice from four months of age. The surface area of the granule layer in the CA2 and CA3 regions was lower in the Spg11 -/than control mice only at 16 months of age . We observed no astrocyte proliferation in these structures.
Spg11 -/mice show spinal cord atrophy and axonal degeneration in the corticospinal tract.
We examined transverse, 0.5 µm semi-thin sections of cervical and lumbar spinal cords of mice of different ages by toluidine blue-staining ( Fig. 5 A and B) . The surface-area and structure of the whole spinal cord of knockout and control mice were similar at four months of age. However, by 16 months of age, the whole spinal cord of Spg11 -/mice showed significant atrophy compared to the Spg11 +/+ mice (Cervical -31,5%, lumbar -29,2%) ( Fig. 5 A-F), as in the brain and cerebellum.
Accordingly, at that stage, the surface-areas of the white and grey matter were lower in both the cervical and lumbar sections of Spg11 -/spinal cords ( Fig. 5E and F). At eight months of age, the
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surface-areas of the white and gray matter in the cervical section of knockout mice were similar to those of the control mice ( Fig. 5 C) . In contrast, at that age, lumbar sections already showed the first signs of atrophy, with a slightly lower surface-area of the white matter than in controls ( Fig. 5 D) .
We then assessed whether the degeneration of the cortico-spinal tracts that occurs in the human SPG11 disease, also occurs in Spg11 knockout mice. We found that the distribution of the nervous fibers of the corticospinal tract was different in Spg11 -/mice compared to that of Spg11 +/+ mice (Fig. 5 G and H) . The percentage of small axons (< 5 µm 2 ) was significantly higher in Spg11 -/mice from eight months of age than in age-matched controls ( Fig. 5 K) . In parallel, the percentage of large axons (> 15 µm 2 ) was significantly lower in the knockout-mice. This pathological phenotype worsened with time ( Fig 
Loss of spatacsin causes loss of lower motor neurons and myofibers.
We , suggesting that these animals exhibit progressive amyotrophy. We observed similar results in the tibialis and plantaris skeletal muscles (data not shown). Accordingly, a grip test that measures traction strength showed that Spg11 -/mice lost muscular strength in both forelimbs and hind limbs from 12 months on ( Fig. 6 P) .
Loss of spatacsin leads to early lysosomal dysfunction.
We then evaluated the cellular alterations underlying neurodegeneration in Spg11 -/mice.
Autofluorescent intracellular material accumulated in the neurons of the cerebral cortex in Spg11 -/mice. We observed this accumulation in six week-old knockout mice, whereas large autofluorescent particles were not detected until the age of 16 months in control mice. At this stage, the deposits in the motor neurons of knockout mice were more numerous and larger than those in control mice ( Fig. Sup 1 A). We did not detect autofluorescence upon excitation at 635 nm ( Fig. Sup 1 B) , so it was possible to analyze its colocalization with various markers. Lamp1 immunoreactivity surrounded the autofluorescent aggregates ( Fig. 7 A) , suggesting that the loss of spatacsin altered lysosomal function.
Lysosomes play a key role in autophagosome degradation, and lysosomal dysfunction is thought to lead to the accumulation of autophagolysosomes (Menzies et al., 2015) . We therefore investigated whether the autofluorescent aggregates colocalized with p62, a marker of autophagy substrates. We observed colocalization of p62 with autofluorescent aggregates only in Spg11 -/mice at 16 months of age ( Fig. 7 B) . We observed similar autofluorescent aggregates surrounded by Lamp1 immunostaining in Purkinje cells in the cerebellum ( cortex and in spinal motor neurons in Spg11 -/mice, but only at late stages of the disease. We further investigated changes in autophagy by carrying out western blotting to determine the levels of LC3-II, the lipidated form of LC3 recruited to autophagosomes. LC3-II levels were similar in control and knockout mice, at all ages ( Fig. 7 C) . Thus, spatacsin loss led to the accumulation of the p62 autophagic marker, but this accumulation seems to be only a late event in the disease process.
We analyzed cortical and spinal neurons by electron microscopy to confirm the alteration of lysosomal function in the brain and spinal cord of Spg11 -/mice ( Fig. 8 ). Lysosomes appeared as electron-dense organelles surrounded by a membrane. We observed in the cortical neurons of twomonth old knockout animals lysosomes containing osmiophilic material, suggesting the presence of
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10 undigested material ( Fig. 8 A) . These lysosomes also contained low-density structures that are consistent with lipid droplets ( Fig. 8 A) . The size of these lipofuscin-like particles strongly increased with age, as did the size of lysosomes containing autofluorescent material ( Fig. 8 A) . We also observed similar lysosomes in spinal motor neurons, Purkinje cells and hippocampal neurons of Spg11 -/mice from the age of two months ( Fig. 8 B and data not shown). These structures were positive for cathepsin D, suggesting a lysosomal origin ( Fig. 8 C) . Similar structures have been observed in a large number of cortical neurons in the brain of an SPG11 patient (Denora et al., 2016) carrying two truncating heterozygous mutations in trans ( Fig. 8 D) , suggesting that they contribute to the neuropathological process. The significant increase in lipid-containing structures in Spg11 -/neurons, even in young animals, suggests that lipid clearance by lysosomes may be impaired.
Spatacsin promotes the clearance of lipids from lysosomes.
We investigated the cellular alterations underlying lysosomal dysfunction in the brains of Spg11 -/mice by studying primary cultures of mouse embryonic fibroblasts and cortical neurons by electron microscopy. The proportion of lysosomes containing osmiophilic material was significantly higher in Spg11 -/fibroblasts ( Fig. 9 A and B ) and neurons ( Fig. 10 A and B) , as observed in the brains of Spg11 knockout mice and human SPG11 patients. We tested whether lysosomes accumulated lipidic material, by labelling lysosomes in fibroblasts and neurons with the Lamp1 antibody and total lipids with Nile red, which stains all neutral and polar lipids (Greenspan et al., 1985) . The proportion of Nile red staining colocalized with lysosomes was higher in Spg11 -/fibroblasts ( Fig These data suggests that the accumulation of lipids in lysosomes of Spg11 -/fibroblasts or neurons was not due to changes in lysosomal pH or cathepsin B activity.
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We hypothesized that spatacsin could play a role in the clearance of lipids from lysosomes. It has been suggested that autophagy shuttles phospholipids of organelle membranes into lysosomes, and that fatty acids hydrolyzed by the lysosomes then accumulate in lipid droplets (Rambold et al., 2015) . We investigated whether autophagy induction affected the accumulation of lipids in lysosomes by monitoring Nile red and Lamp1 staining. We observed an accumulation of lipids in lysosomes two and six hours after amino-acid deprivation, followed by lipid clearance from lysosomes and the accumulation of lipid droplets ( Fig. 9 C and D) . Inhibition of lysosomal enzymes by pH neutralization with bafilomycin A1 blocked lipid clearance from the lysosomes, confirming that lipid clearance from lysosomes occurred actively (data not shown). Lipids were cleared significantly more slowly from the lysosomes of Spg11 -/fibroblasts than control cells, suggesting a role for spatacsin in lysosomal lipid clearance ( Fig. 9 D) . Consistent with these findings, the number of lipid droplets was smaller in Spg11 -/than control cells after 24 hours of amino-acid starvation ( Fig. 9 E) . In untreated cells, the number of lipid droplets was also smaller in Spg11 -/fibroblasts or primary cortical neurons than in control cells ( Fig. 9 E and 10 E), also suggesting a role for spatacsin in the clearance of lipids from lysosomes under basal conditions.
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Discussion:
Loss of function mutations in SPG11 cause a large variety of phenotypes ranging from pure to complex forms of motor neuron diseases, including pure forms of HSP, juvenile-onset ALS or CMT and complex forms of HSP associated with mental impairment or cognitive decline, neuropathy and abnormal MRI features (Montecchiani et al., 2016; Orlacchio et al., 2010; Stevanin et al., 2008) . The most striking and common clinical hallmark observed in SPG11 patients is gait disturbance with motor difficulties generally developing in the two first decades of life. Most patients display progressive spasticity of the lower limbs associated with severe muscular weakness. In the Spg11 -/mouse model generated in this study, behavioral tests revealed progressive gait impairment and motor dysfunction, beginning at the age of six weeks, consistent with the first symptoms detected in human patients before the age of 10 years. This phenotype was associated with progressive neurodegeneration in the motor cortex and cerebellum, as well as the presence of dystrophic axons in the corticopinal tract.
SPG11 patients also frequently present peripheral neuropathy associated with distal muscle wasting, in particular when diagnosed with juvenile-onset ALS or CMT. In agreement, the Spg11 -/mouse model described here also presented a progressive loss of large motor neurons in the grey matter of the lumbar spinal cord and a high proportion of fragmented neuromuscular junctions. This degeneration together with the loss of muscular strength in 12-month old Spg11 -/mice is consistent with a late ALS-like phenotype in the Spg11 mouse model. However, the homogenous decrease in the cross section of myofibers in Spg11 -/mice suggests that muscular atrophy was not a consequence of denervation of individual fibers. Spatacsin may thus play a more general role in muscle physiology, and the loss of function of this protein could directly result in muscular atrophy. Our observation in the
Spg11
-/mouse model is also consistent with the mental impairment observed in most SPG11 patients and the worsening cognitive decline as the disease progresses (Siri et al., 2010; Stevanin et al., 2008; Stevanin et al., 2006) . The cognitive impairment in the mouse was associated with the early atrophy of the hippocampus.
The Spg11 mouse model we characterized develops motor deficits much earlier than the Spg11-knockout mouse developed by Varga et al. (Varga et al., 2015) . We also observed degeneration of lower motor neurons and thinning of the corpus callosum that were absent in the model of Varga et al., as well as cognitive impairment that was not reported. The discrepancies between the two models may be due to the strategy used to inactivate Spg11. Varga et al. inactivated 
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Spg11 by inserting a genetrap cassette in the first intron of the gene, whereas we inserted stop codons in exon 32 to mimic the most frequent mutation observed in SPG11 patients (Hehr et al., 2007; Stevanin et al., 2008) . The effects of these two types of mutations on some spatacsin isoforms may account for the differences in the results obtained by these two studies. The construct used by Varga et al. was predicted to encode a cytoplasmic fusion protein of the 82 N-terminal amino acids of spatacsin with βgeo (Varga et al., 2015) . We could not verify whether the insertion of stop codons in exon 32 led to the production of a truncated protein or complete degradation of the mutant protein, because the antibody we used recognizes the C-terminal domain of spatacsin. The difference between the two studies reflects the remarkable range of phenotypes observed in humans. Indeed, no genotype-phenotype correlation has been shown in SPG11 patients. The same mutations can lead to different phenotypes in the same family (Daoud et al., 2012) and mutations in different parts of the SPG11 gene lead to the same pathology (Stevanin et al., 2008; Stevanin et al., 2007) . Other factors, such as environmental, genomic, or epigenetic factors, may contribute to the variability of phenotypes found in SPG11 patients, and could contribute to the difference in the phenotype observed between our Spg11 mouse model and that developed by Varga et al.
Histological and electron microscopy analyses showed the presence of cellular dysfunction in young animals, before neuronal death occurred. In the neurons of Spg11 -/animals, we observed autofluorescent particles that were surrounded by the lysosomal marker Lamp1 and organelles that contained lipidic material by electron microscopy. The size of both markers increased with age, suggesting that they are the same structure. There was no significant difference in the levels of the autophagy marker LC3-II in brains of the Spg11 -/mice relative to controls. It is however possible that mild changes in the autophagy pathway occur during disease progression, explaining the large accumulation of lipids and p62 in lysosomes in 16-month-old Spg11 -/mice, as well as in the brains of SPG11 patients (Denora et al., 2016) .
Our data show that lipids accumulate in lysosomes very early in development. Indeed, they were already detected in cultured Spg11 -/fibroblasts and neurons obtained from embryos. This may contribute in the long term to the generation of lipofuscin that has been proposed to be composed of numerous lipid species (Sulzer et al., 2008) . How the loss of spatacsin function leads to the accumulation of lipids in lysosomes remains to be determined. The absence of spatacsin did not alter lysosomal pH nor impair cathepsin B catalytic activity. Artificial activation of autophagy in mouse embryonic fibroblasts resulted in the transient accumulation of lipids in lysosomes and the formation of lipid droplets, as observed in other models (Rambold et al., 2015) . The clearance of lipids from lysosomes was lower in absence of spatacsin, which may account for the slight accumulation of lipids in lysosomes and the smaller number of lipid droplets at steady state. We were unable to promote lipid accumulation in lysosomes upon starvation in cultured neurons, because they do not respond to this stimulus (data not shown), as previously reported (Mizushima et al., 2004) . Nevertheless, the change in lipid metabolism was evident under basal conditions, suggesting that the loss of spatacsin function impaired lipid clearance from lysosomes in neurons as well.
The mechanism for spatacsin-mediated clearance of lipids from lysosomes remains enigmatic,
especially as the precise subcellular localization of spatacsin is still debated (Chang et al., 2014; Khundadze et al., 2013; Sagona et al., 2010; Slabicki et al., 2010; Vantaggiato et al., 2013) . We hypothesize that spatacsin acts as a lipid transporter as it has been proposed to have transmembrane regions (Stevanin et al., 2007) and has been found to be localized in lysosomes (Hirst et al., 2013) .
Alternatively, the proposed role of spatacsin in autolysosome reformation (Chang et al., 2014) could play a role in sorting lipids within lysosomes. However, it was not possible to evaluate whether these tubular lysosomal structures contained lipids, detected by Nile Red staining, because of their small diameter. The absence of spatacsin function may also deregulate lysosomal protein machinery implicated in lipid egress, which remains to be identified, possibly through a disturbance in membranetrafficking, which is altered in SPG11 cells (Perez-Branguli et al., 2014) .
Regardless of the molecular mechanism involved, the loss of spatacsin function resulted in the presence of fewer lipid droplets. Changes in lipid droplet metabolism have been reported for other proteins associated with the physiopathology of HSP, such as spastin, atlastin1, REEP1 and spartin (Falk et al., 2014; Klemm et al., 2013; Papadopoulos et al., 2015; Renvoise et al., 2016; Renvoise et al., 2012) . It would be informative to investigate whether the changes in lipid droplet number or size reflect changes in lysosome-mediated lipid trafficking in these models, as in the Spg11 -/mouse model.
Proteins linked to the biogenesis of lipid droplets were identified as neurotoxicity modifiers associated with VAPB, a gene mutated in ALS8 (Sanhueza et al., 2015) . It would be worthwhile to investigate whether lysosomal function and lipid droplet metabolism are also altered in various ALS mouse models to better understand the overlap between SPG11/ALS5 and typical ALS pathology.
In conclusion, the Spg11 -/mouse model presented here recapitulates the full set of symptoms observed in human HSP, CMT and juvenile-onset ALS and is therefore a good model to investigate the mechanisms underlying their physiopathology. Examination of the cellular alterations observed in this model suggests that the loss of spatacsin function alters lipid metabolism in lysosomes. Our study therefore links two of the main themes, lysosome dysfunction and lipid metabolism, that are recurrent in the function of proteins encoded by the numerous genes associated with HSP and opens common avenues of research for future therapy linked to lipid turnover.
Methods:
Generation and breeding of Spg11 knockout mice.
Spg11-knockout mice were generated as previously described (Schnutgen et al., 2003) . The gene targeting vector was constructed by inserting a fragment corresponding to mouse exon 32 to exon 34 (sv129 genetic background) into intron 34 in an inverse orientation, with c.6052C>T and c.6061C>T substitutions in exon 32 (Fig. 1A) . MCI-129Sv/Pas ES cell lines were transfected with the resulting construct and screened by Southern blotting and PCR. Homologous recombinant clones were injected into blastocysts. Chimeric mice were mated with C57BL/6 females to obtain germline transmission.
The Neo selection cassette was removed by crossing with a flp-expressing mouse. The ubiquitous insertion of exon 32-bearing stop mutations was achieved by crossing the mice with a line expressing
Cre recombinase under the control of the CMV promoter. Heterozygous mice were then backcrossed with C57BL/6N mice for 10 generations.
Genotyping was performed by PCR with the 5'GCCAAGGTATGCACCAGACGGGG3' and 5'TCCTGCCCTTCACCACGTCAGG3' primers. PCR products of 493 and 434 bp were obtained for the invalidated and wild-type alleles, respectively. Mice were housed in same-sex groups and maintained on a 12-h light/12-h dark cycle with unrestricted access to food and water.
Behavioral evaluation.
At least 10 animals per genotype and per age were tested. All behavioral procedures were performed between 8:00 a.m. and 1:00 p.m. Bias was minimized by randomly testing mice in experimental cohorts, regardless of their genotype. The treadmill test was performed with an apparatus consisting of a plastic chamber containing a 416 cm treadmill (CleverSys). The mice were tested individually at a controlled speed of 10 cm.s -1
. After a 1-min habituation phase, the gait of the mice was recorded for 20 s (80 frames per s, BCam). Gait was analyzed using GaitScan software (CleverSys). The motor deficit was also evaluated with a Rotarod apparatus (accelerating model LE8200, Bioseb). Mice were placed on the accelerating rod at a starting speed of 4 rpm. The final speed of 40 rpm was reached within 5 min. Mice were tested on two consecutive days, in five trials per day, with an interval of 15 min between trials. The duration for which they were able to remain on the rod was recorded. Muscle strength was recorded with a grip test system (Dual Sensor 1027CD-M, Colombus, Linton Instrumentation). When the animal firmly gripped the triangular metal rod, the experimenter gently pulled its tail horizontally until the animal released its hold. The maximum traction force (mN) developed by the forelimbs and hindlimbs was recorded.
Antibodies.
Antibodies used in the study were: rabbit anti-spatacsin (Protein Tech, directed against aa 2094-2443 of human spatacsin); rabbit anti-spastizin (Murmu et al., 2011) ; mouse anti--tubulin (Abcam); mouse anti-NeuN (Millipore); rabbit anti-GFAP (DAKO); monoclonal mouse anti-Calbindin, 1:300, (Swant); goat anti-Choline acetyltransferase (ChAT), 1:500, (Millipore); rabbit anti-Neurofilament-L, 1:100, (Millipore); mouse Alexa Fluor® 488 conjugated anti-Synaptophysin, 1:25, (Millipore); rat anti-Lamp1 (Clone 1D4B), mouse anti-p62 (Abcam); rabbit anti-LC3 (Novus Biologicals); goat anti-caspase-3 (Millipore). For immunoblotting, the secondary antibodies were conjugated to horseradish peroxidase (Jackson Laboratories) or fluorochromes (IR-dye 800 or IR-dye 680; LI-COR). Secondary antibodies used for immunofluorescence were purchased from Life Technologies.
Histological and immunohistochemical analyses.
Mice were anesthetized by the intraperitoneal injection of 1/6 2% xylazine (Rompun), 1/3 ketamine (10 mg.ml -1 , Imalgen 1000) in phosphate-buffered saline (PBS) and were subjected to intracardiac perfusion of 4% paraformaldehyde in PBS.
For immunostaining analysis, the brains and spinal cords were dissected and post-fixed by incubation for 24 h in 4% paraformaldehyde and 24 h in 30% sucrose PBS. Slices (20 µm for brain and 40 µm for lumbar spinal cord) were cut on a freezing microtome (Microm HM450, Thermo Scientific) and maintained in 0.02% sodium azide in PBS at 4°C. After 90 min incubation in blocking solution, sections were incubated with primary antibodies in 2% BSA/0.25% Triton X-100 in PBS overnight at 4°C. After washing, the sections were incubated with the secondary antibodies for 90 min at room temperature, and mounted in Fluoromount-G mounting medium (Southern Biotechnology).
Staining specificity was determined by incubation in the absence of primary antibodies.
Whole-mount preparations of muscle fibers were stained for motor endplates with Alexa Fluor® 555-conjugated -bungarotoxin 1:500 (Life technologies) and for presynaptic motor nerve terminals with anti-Neurofilament L and anti-Synaptophysin antibodies in 2% BSA/0.5% Triton X-100
Glycin 0.15% in PBS 48 h at 4°C. After washing, the sections were incubated with the secondary antibodies for 60 min at room temperature, and mounted in Fluoromount-G mounting medium (Southern Biotechnology).
For morphological analysis, cervical (C1 to C7) and lumbar (L1 to L5) parts of the spinal cords were placed in 2% glutaraldehyde for 24 h. They were then embedded in EPON resin and 1 µm-thin sections were stained with toluidine blue for 1 h.
For muscle typology, soleus muscles were frozen into NEG-50 TM (Thermo Scientific) at -60°C.
Transversal sections (10 µm) of the medial part of the muscle were prepared with a Leica CM3050S cryostat and stained with Hematein for 3 min and Eosin for 1 min.
The surface-areas of the brains or brain regions were determined using NDPview software.
Counting of cell populations was performed using ImageJ software. Spinal motor neuron, neuromuscular junction, and corticorspinal tract images were collected with a Leica DFC500 camera mounted on a Leica DM4000B microscope with 40X, 60X and 100X objectives. Whole spinal cord and muscle Images were obtained with a NanoZoomer 2.0-RS (Hamamatsu) equipped with a 20X objective. Identical brightness, contrast and color balance adjustments were applied to all groups.
Confocal images were acquired with an Olympus FV-1000 confocal laser scanning microscope, with a 60X objective. Autofluorescence was triggered by excitation with a 488 nm laser.
Cell biology.
Mouse embryonic fibroblasts and primary cultures of cortical neurons were prepared as previously described (Gautier et al., 2012) . Immunostaining was performed after six days of culture in vitro, as previously described (Murmu et al., 2011) . For lipid staining, cells were incubated for 1 h with Nile Red 
Electron microscopy.
Briefly, mice were anaesthetized and sacrificed by intracardiac perfusion with a solution of 4% paraformaldehyde in 0.1 M phosphate buffer at pH7.4. Samples from the frontal cortex and spinal cord were fixed in 1% glutaraldehyde in the same buffer, post-fixed in 2% osmium tetroxide, dehydrated, and
A C C E P T E D M A N U S C R I P T
20 embedded in Araldite. Ultrathin sections were stained with uranyl acetate and lead citrate and examined by a Hitashi transmission electron microscope. To analyze cultured fibroblasts and neurons, cells were fixed with 2.5% glutaraldehyde in PBS for 2 h at 22°C. The cells were then post-fixed in 1% osmium tetroxide for 20 min, rinsed in distilled H 2 O, dehydrated in 50% and 70% ethanol, incubated in 1% uranyl acetate for 30 min, processed in graded dilutions of ethanol (95-100%, 5 min each), and embedded in Epon. Ultrathin (70 nm) sections were cut, stained with uranyl acetate and lead citrate, and analyzed with a JEOL 1200EX II electron microscope at 80 kV.
Western blot analysis.
Cells or tissues were lysed by incubation in 100 mM NaCl, 10 mM Tris HCl pH 7.4, 1 mM EGTA, 2 mM MgCl 2 , 1% SDS, and Halt™ Protease Inhibitor Cocktail (Thermo Scientific) for 5 min at room temperature. Western blotting was performed as described previously (Esteves et al., 2014) .
Signals were visualized with a chemiluminescence substrate (SuperSignal West Dura), or acquired with an Odyssey ClX (Li-COR). Signal intensities were quantified using ImageJ software.
Statistics.
All values are displayed as the means ± SEM within each group. A Kolmogorov-Smirnov normal distribution analysis was first performed on all data. Data sets were compared using the Kruskal-Wallis test for nonparametric data sets and the 2-tailed Student's t-test for parametric data sets (Systat version 8.0; SPSS Inc., Chicago, IL, USA). For cellular experiments, two-way ANOVA followed by the Holm Sidak test was used to analyze differences between genotypes at different time points. A P value of 0.05 or less was considered to be statistically significant.
Study approval.
The care and treatment of animals followed the N° 2010/63/UE European legislation and national authority (Ministère de l'agriculture, France) guidelines for the detention, use, and ethical treatment of laboratory animals. All the experiments were approved by the local ethics committee (Ce5/2012/045 approval number) and experiments were conducted by authorized personnel. Patient-derived material was obtained through procedures approved by the ethics committee with the written, informed consent of the family (approval SST04/11/04052011). (J-L) CA1 (J), CA2+CA3 (K), and dentate gyrus (L) granule layer surface-areas. The surface-area of CA1 and the dentate gyrus granule layer were affected by atrophy from four months of age in knockout mice compared to control mice (n ≥ 5 slices/animal and n ≥ 5 animals/genotype/age; Kruskal-Wallis test; *p ≤ 0.05). (P) Grip test. Spg11 -/mice showed a significant loss of muscular strength in both forelimbs and hindlimbs from 12 months of age compared to control mice ( n≥ 12 animals/genotype/age; Kruskal-Wallis test; **p ≤ 0.01 and ***p ≤ 0.001). 
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